Serono's Rebif gets approval for earlier use in multiple sclerosis

By Elaine Rigoli

Tampa, Fla., July 10 - The European Commission has approved Serono's Rebif for prescription after the diagnosis of multiple sclerosis (MS) has been confirmed based on one attack and subsequent positive magnetic resonance imaging scans.

Previously, Rebif was approved in the European Union for patients who had experienced at least two attacks.

"MS has an initial stage when clinical manifestations are not pronounced but irreversible neurological damage is taking place. This neurological damage determines the relative risk of progression of the disease. People with MS living in Europe will be able to benefit from the proven efficacy of Rebif as soon as MS is diagnosed, when it is needed most," senior executive vice president Roberto Gradnik said in a news release.

The European Commission decision means that Rebif is valid immediately in all 25 member states of the European Union.

Serono is a biotechnology company based in Geneva, Switzerland.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.